Table 1 Baseline characteristics of the trial population
Characteristic | Septoplasty (with or without concurrent turbinate surgery), N = 102 | Non-surgical management, N = 101 |
|---|---|---|
Age, years | ||
 Mean ± SD | 39 ± 14 | 37 ± 15 |
 Range | 18 to 67 | 18 to 70 |
Male sex, no. (%) | 73 (72) | 66 (65) |
Body mass index | ||
 Mean ± SD | 25.0 ± 4.5 | 25.6 ± 3.8 |
 Range | 16.7 to 39.9 | 17.5 to 38.7 |
Duration of nasal obstruction, years | ||
 Median | 6 | 8 |
 IQR | 10 | 11 |
Nasal obstruction bilateral, no. (%) | 64 (63) | 61 (60) |
Previous treatment for nasal obstruction, no. (%) | 81 (79) | 87 (86) |
 Local corticosteroids, no. (%) | 73 (72) | 73 (72) |
 Nasal decongestants, no. (%) | 39 (38) | 42 (42) |
 Turbinate surgery, no. (%) | 2 (2) | 3 (3) |
History of nasal trauma, no. (%) | 42 (41) | 42 (42) |
Smoking status | ||
 Current smoker, no. (%) | 26 (25) | 34 (34) |
 History of smoking, no. (%) | 34 (33) | 30 (30) |
Cocaine abuse, no. (%) | 7 (7) | 11 (11) |
Snoring†, no. (%) | 50 (49) | 44 (44) |
Allergic rhinitis†, no. (%) | 32 (31) | 30 (30) |
Asthma†, no. (%) | 24 (24) | 18 (18) |
Turbinate hypertrophy, no. (%) | 46 (45) | 47 (47) |
 Unilateral, no. (%) | 29 (28) | 24 (24) |
 Bilateral, no. (%) | 16 (16) | 18 (18) |
Septal deviation bilateral, no. (%) | 25 (25) | 23 (23) |
Septal deviation severity‡ | ||
 Mild, no. (%) | 32 (31) | 27 (27) |
 Moderate, no. (%) | 66 (65) | 67 (66) |
 Severe, no. (%) | 37 (36) | 32 (32) |
Measures of effectiveness | ||
 EQ-5D-3L utility score, mean ± SD | 0.83 ± 0.19 | 0.82 ± 0.19 |
 EQ-5D-3L VAS, mean ± SD | 72.1 ± 16.1 | 74.1 ± 17.0 |
 NOSE, mean ± SD | 32.8 ± 18.1 | 34.4 ± 19.3 |
 PNIF, mean ± SD§ | 91.6 ± 39.0 | 87.1 ± 40.5 |